Rahway, USA- Merck, recognized as MSD globally, has announced the commencement of pivotal Phase 3 trials for four investigational candidates across hematologic malignancies and solid tumors. The company is actively enrolling participants in global Phase 3 studies for the following candidates:
Bomedemstat: An investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, assessed for treating specific patients with essential thrombocythemia (ET). Nemtabrutinib: An investigational oral, reversible, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, under evaluation for treating certain patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). MK-2870: An investigational trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC), developed in collaboration with Kelun-Biotech, being studied for specific patients with non-small cell lung cancer (NSCLC) and those with previously treated endometrial carcinoma. MK-5684: An investigational CYP11A1 inhibitor developed in collaboration with Orion, under evaluation for treating certain patients with metastatic castration-resistant prostate cancer (mCRPC).
Also Read: Everyone Can Take Action Against Blood Cancer
“These Phase 3 trial initiations for four of our investigational candidates represent a critical step forward in our efforts to advance potential treatment options for people with solid tumors and hematologic neoplasms and malignancies,” said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. “We have a proud legacy of turning breakthrough science into medicines that save and improve lives around the world. We are dedicated to continuing research to expand our broad portfolio of oncology therapeutics, addressing unmet needs in cancer care.”
